

**PATIENT GROUP DIRECTION**

Issued under Part 2 of the Medicines (Prescription Only) Regulations, 1987 by the Director of Public Health with the consent of the Minister  
for

# Measles, mumps and rubella (MMR) vaccine

## Patient Group Direction (PGD)

LEGAL STATEMENT			
Protocol Issuer	Director of Public Health Gibraltar Health Authority St. Bernard's Hospital Gibraltar Contact Telephone: +(350) 20079160		
Date effective	11 <sup>th</sup> April 2025		
Date of expiry	11 <sup>th</sup> April 2027		
Staff characteristics	See below (section 1)		
Professional Authorisation	SIGNATURE	DATE	
Lead Doctor	Dr Helen Carter Director of Public Health <sup>1</sup>		
In Consultation with	SIGNATURE	DATE	
Lead Pharmacist	Ms Melanie Gordon Chief Pharmacist		
Lead Nurse	Ms Sandra Gracia Director of Nursing		
Legal Authorisation	SIGNATURE	DATE	
With the consent of Minister	The Honourable Minister for Health Gemma Arias- Vasquez <sup>2</sup> MP		

<sup>1</sup> A Patient Group Direction issued shall only have effect if it is signed by the Director of Public Health with the consent of the Minister.

<sup>2</sup> See footnote 1.

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

## 1. Characteristics of staff

<b>Qualifications and professional registration</b>	Registered professional with one of the following bodies: <ul style="list-style-type: none"> <li>• nurses or midwives currently registered with the Gibraltar Nursing Registration Board (NRB)</li> <li>• practitioners currently registered with the Gibraltar Medical Registration Board (MRB)</li> <li>• Anyone deemed by the Director of Public Health to be competent who meets the additional requirements below.</li> </ul>
<b>Additional requirements</b>	<ul style="list-style-type: none"> <li>• Additionally practitioners: must be authorised by name as an approved practitioner under the current terms of this PGD before working to it</li> <li>• must have undertaken appropriate training for working under PGDs for supply/administration of medicines</li> <li>• must be competent in the use of PGDs (see <a href="#">NICE Competency framework</a> for health professionals using PGDs)</li> <li>• must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC)</li> <li>• must be familiar with, and alert to changes in relevant chapters of Immunisation Against Infectious Disease: the <a href="#">Green Book</a></li> <li>• must be familiar with, and alert to changes in the relevant GHA standard operating procedures (SOPs) and arrangements for the Gibraltar small pox vaccination programme</li> <li>• must have undertaken training appropriate to this PGD as required by local policy and national NHS standard operating procedures</li> <li>• must be competent to assess individuals for suitability for vaccination, identify any contraindications or precautions, obtain informed consent (or 'best interests' decision in accordance with the Lasting Powers of Attorney and Capacity Act 2018 and the Mental Health Act 2016) and to discuss issues related to vaccination</li> <li>• must be competent in the correct handling and storage of vaccines, and management of the cold chain</li> <li>• must be competent in the handling of the vaccine product, procedure for dilution of the vaccine and use of the correct technique for drawing up the correct dose</li> <li>• must be competent in the injection technique</li> <li>• must be competent in the recognition and management of anaphylaxis, have completed basic life support training and be able to respond appropriately to immediate adverse reactions</li> <li>• must have access to the PGD</li> <li>• should fulfil any other additional requirements defined by local policy</li> </ul> <p><b>THE INDIVIDUAL PRACTITIONER MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT</b></p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

<b>Continued training requirements</b>	<ul style="list-style-type: none"> <li>Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD).</li> <li>Practitioners should be constantly alert to any subsequent recommendations from Public Health Gibraltar and/or the GHA and other sources of medicines information.</li> </ul> <p>Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD.</p>
--	--

## 2. Clinical condition or situation to which this PGD applies

<b>Clinical condition or situation to which this PGD applies</b>	Indicated for the active immunisation of individuals from 1 year of age for routine immunisation, or from 6 months of age if early protection is required, for the prevention of measles, mumps and/or rubella in accordance with the national immunisation programme, <a href="#">Guidelines on post-exposure prophylaxis</a> for measles and recommendations given in <a href="#">Chapter 21</a> , <a href="#">Chapter 23</a> and <a href="#">Chapter 28</a> of Immunisation Against Infectious Disease: the 'Green Book'.
--	--

<b>Criteria for inclusion</b>	<p>Individuals who:</p> <ul style="list-style-type: none"> <li>are aged 1 year (on or after their first birthday) or older and are either unimmunised or have incomplete, uncertain or unknown vaccination status against MMR</li> <li>are between 6 months and 1 year of age and early protection is considered necessary, such as due to travel or outbreak</li> <li>are aged 6 months and over and vaccination is indicated for measles post-exposure prophylaxis in accordance with recommendations from the UKHSA</li> </ul> <p>*See <a href="#">Special considerations / additional information</a> section for further detail on patient groups at particular risk from measles, mumps or rubella infection and opportunities to check immunisation status and vaccinate as appropriate.</p>
-------------------------------	---

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

	In an outbreak situation, under written instruction from the Director of Public Health, specific additional groups of the population may be offered an inactivated seasonal influenza vaccine as specified in the written instruction.
--	--

<b>Criteria for exclusion<sup>3</sup></b>	<p>Individuals who:</p> <p>whom valid consent, or 'best-interests' decision in accordance with the <a href="#">Lasting Powers of Attorney and Capacity Act 2018</a> and the <a href="#">Mental Health Act 2016</a>, has not been obtained (for further information on consent see <a href="#">Chapter 2</a> of '<a href="#">The Green Book</a>').</p> <p>Have had a confirmed anaphylactic reaction to a previous dose of any measles, mumps or rubella containing vaccine or to any components of the vaccine, these may include neomycin or gelatin (refer to relevant SPC).</p> <p>Are known to be pregnant.</p> <p>Have a primary or acquired immunodeficiency state (see the 'Green Book' <a href="#">Chapter 6</a> for more detail).</p> <p>Are on current or recent high dose immunosuppressive or biological therapy (see the 'Green Book' <a href="#">Chapter 6</a> for more detail).</p> <p>Have received varicella, zoster or yellow fever vaccine in the preceding 4 weeks, unless protection against measles is required rapidly (see Drug Interactions).</p> <p>Have received blood products, such as immunoglobulins, in the preceding 3 months, unless protection against measles is required rapidly (see Drug Interactions).</p> <p>Are awaiting reading of a tuberculin (Mantoux) skin test, unless protection against measles is required rapidly (see Drug Interactions).</p> <p>Are suffering from acute severe febrile illness (the presence of a minor I</p>
---	--

<sup>3</sup> Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027



<p><b>Action to be taken if the patient is excluded</b></p>	<p>Individuals who have had a confirmed anaphylactic reaction to a previous dose of MMR vaccine or any components of the vaccine should be referred to a clinician for specialist advice and appropriate management.</p> <p>Individuals who are pregnant should be advised to avoid contact with known or suspected cases of measles, mumps and rubella infection and report any rash illness or contact with rash illness to their GP and/or midwife. Women who are lacking two documented doses of MMR should be immunised after their pregnancy, at the earliest opportunity and before any further pregnancies. Note: MMR can be given to breast-feeding mothers without any risk to their baby.</p> <p>Individuals who have a primary or acquired immunodeficiency state or who are currently, or were recently, on high dose immunosuppressive or biological therapy (see <a href="#">Chapter 6</a>): consult appropriate specialist regarding the individual's immune status and suitability for receiving live MMR vaccine. Administration may be indicated in some cases – a PSD will be required.</p>
---	---

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

	<p>Individuals who have been immunised against varicella, zoster or yellow fever within the last 4 weeks, or received blood products in the preceding 3 months, and do not require rapid protection against MMR, defer immunisation until appropriate interval (see <a href="#">Drug Interactions section</a>).</p> <p>Individuals who are awaiting reading of a tuberculin (Mantoux) test, should delay MMR vaccination until the skin test has been read unless protection against measles is required urgently.</p> <p>Individuals suffering acute severe febrile illness should postpone immunisation until they have recovered; immunisers should advise when the individual can be vaccinated and ensure another appointment is arranged.</p> <p>Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual's clinician as appropriate.</p> <p>The risk to the individual of not being immunised must be taken into account.</p> <p>Document the reason for exclusion and any action taken in the individual's clinical records.</p> <p>Inform or refer to the GP or a prescriber as appropriate.</p>
--	---

<b>Action to be taken if the patient or carer declines treatment</b>	<p>In case of postponement due to acute severe febrile illness, advise when the individual can be vaccinated and ensure another appointment is arranged. Seek appropriate advice from the Director of Public Health or the individual's clinician where appropriate.</p> <p>The risk to the individual of not being immunised must be taken into account.</p> <p>Document the reason for exclusion and any action taken in the individual's clinical records.</p> <p>Inform, or refer to, the GP or a prescriber as appropriate.</p> <p>Informed consent, from the individual or a person legally able to act on the person's behalf, must be obtained for each administration. Where a person lacks the capacity, in accordance with the <a href="#">Mental Capacity Act 2018</a>, a decision to vaccinate may be made in the individual's best interests. For further information on consent see <a href="#">Chapter 2</a> of '<a href="#">The Green Book</a>'.</p>
--	---

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

	<p>Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications. Document advice given, and the decision reached.</p> <p>Inform, or refer to the GP or a practitioner as appropriate.</p>
<b>Arrangements for referral for medical advice</b>	As per GHA policy

### 3. Description of treatment

<b>Name, strength &amp; formulation of drug</b>	<p>Measles, mumps and rubella vaccine (live):</p> <ul style="list-style-type: none"> <li>• Priorix®, powder and solvent for solution for injection in a pre-filled syringe</li> <li>• MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe</li> </ul>
<b>Legal category</b>	Prescription only medicine (POM)
<b>Black triangle</b>	No
<b>Off-label use</b>	<p>Administration to infants between 6 months and 9 months of age is off-label but is in accordance with <a href="#">Guidance for measles post exposure</a> prophylaxis and recommendations given in <a href="#">Chapter 21</a>, <a href="#">Chapter 23</a> and <a href="#">Chapter 28</a> of Immunisation Against Infectious Disease: the 'Green Book'.</p> <p>Vaccine should be stored according to the conditions detailed in the Storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to <a href="#">Vaccine Incident Guidance</a>. Where vaccine is assessed in accordance with these guidelines as appropriate for continued use this would constitute off-label administration under this PGD.</p> <p>Where a vaccine is recommended off-label, consider as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence.</p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027





	<p>The response to MMR in infants is sub-optimal where the vaccine has been given before 1 year of age. If a dose of MMR is given before the first birthday, then this dose should be ignored. Two further doses of MMR should be given at the recommended ages in accordance with the routine schedule (at 1 year of age and a pre-school dose at three years four months).</p> <p>Children who are travelling to epidemic or endemic areas, or who are a contact with a probable or confirmed case of measles, who have received one dose of MMR at the routine age should have the second dose brought forward to at least one month after the first. If the child is given the second dose at less than 15 months of age, then another routine dose (a third dose) should be given after 18 months of age in order to ensure full protection.</p>
<b>Duration of treatment</b>	<p>2 doses of 0.5ml at the recommended interval (see <a href="#">Dose and frequency of administration</a> above).</p> <p>Doses that are administered earlier than the routine schedule, given within 4 weeks of previous yellow fever, varicella or zoster vaccine, or within 3 months of receiving blood products (see <a href="#">Drug interactions section</a>), may need to be repeated</p>
<b>Quantity to be supplied / administered</b>	Single 0.5ml dose per administration.
<b>Supplies</b>	<p>GHA clinics should order/receive MMR vaccines from the SBH Pharmacy dept.</p> <p>The Pharmacy dept will source the vaccine via the national appointed supply route for the GHA.</p> <p>NHS/GHA standard operating procedures should be followed for appropriate ordering, storage, handling, preparation, administration and waste minimisation</p> <p>of BCG Vaccine, which ensure use is in accordance with the product's SPC and</p> <p>official national/GHA recommendations ( see Green Book <a href="#">Chapter 3</a>).</p>
<b>Storage</b>	<p>Store between +2°C to +8°C.</p> <p>Store in original packaging in order to protect from light.</p> <p><b>Do not freeze.</b></p> <p>After reconstitution, the vaccine should be administered promptly or stored between +2°C to +8°C and used within 8 hours of reconstitution. If not used after this time it should be discarded.</p> <p>In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. Refer to <a href="#">Vaccine Incident Guidance</a>.</p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

<b>Disposal</b>	<p>Follow local clinical waste policy and GHA/NHS standard operational procedures and ensure safe and secure waste disposal.</p> <p>Equipment used for immunisation, including used vials, ampoules, or discharges vaccines in a syringe or applicator, should be disposed of safely in a UN-approved puncture-resistant 'sharps' box, according to local authority arrangements and guidance in the technical memorandum 07-01: Safe management of healthcare waste (Department of Health, 2013).</p>
<b>Drug interactions</b>	<p>Immunological response may be diminished in those receiving immunosuppressive treatment.</p> <p>May be given at the same time as inactivated vaccines or at any interval before or after.</p> <p>MMR may attenuate the response to other live vaccines see Table 11.3 in <a href="#">Chapter 11</a> of the 'Green Book' for the recommended time intervals when giving more than one live attenuated vaccine. Where protection against measles is required rapidly then the vaccines should be given at any interval. As the response may be suboptimal if given within 4 weeks of previous yellow fever, varicella or zoster vaccine, an additional dose of MMR should be considered.</p> <p>If protection against measles is urgently required, then the benefit of protection from the vaccine outweighs the potential interference with a tuberculin test. In this circumstance, the individual interpreting the negative tuberculin test should be made aware of the recent MMR vaccination when considering how to manage that individual.</p> <p>When MMR is given within 3 months of receiving blood products, such as immunoglobulin, the response to the measles component may be reduced. This is because such blood products may contain significant levels of measles-specific antibody, which could then prevent vaccine virus replication. Where possible, MMR should be given at least three weeks before or deferred until three months after receipt of such products. If immediate measles protection is required in someone who has recently received a blood product, MMR vaccine should still be given. To confer longer-term protection, MMR should be repeated after three months. A detailed list of drug interactions is available in the SPC, which is available from the <a href="#">electronic Medicines Compendium website</a></p>
<b>Identification &amp; management of adverse reactions</b>	<p>The most common adverse reactions are fever and injection site reactions including pain, swelling and erythema.</p> <p>Malaise, fever and/or a rash may occur, most commonly about a week after immunisation, and last about two to three days. In studies parotid swelling occurred in about 1% of children of all ages up to four years, usually in the third week.</p> <p>Events due to the measles component occur 6 to 11 days after vaccination. Events due to the mumps and rubella components usually occur two to three weeks after vaccination but may occur up to six weeks after</p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

	<p>vaccination. Individuals with vaccine-associated symptoms are not infectious to others.</p> <p>Adverse reactions are considerably less common after a second dose of MMR vaccine than after the first dose.</p> <p>Hypersensitivity reactions and anaphylaxis can occur but are very rare.</p> <p><b>Rare and more serious events</b></p> <p>Febrile seizures are the most commonly reported neurological event following measles immunisation. Seizures occur during the sixth to eleventh day in 1 in 1000 children vaccinated with MMR.</p> <p>Arthropathy (arthralgia or arthritis) has also been reported to occur rarely after MMR immunisation, probably due to the rubella component. If it is caused by the vaccine, it should occur between 14 and 21 days after immunisation. Where it occurs at other times, it is highly unlikely to have been caused by vaccination.</p> <p>ITP has occurred rarely following MMR vaccination, usually within six weeks of the first dose and resolves spontaneously. The risk of developing ITP after MMR vaccine is much less than the risk of developing it after infection with wild measles or rubella virus (see Cautions).</p> <p>Further details on adverse reactions following MMR vaccine can be found in the 'Green Book' <a href="#">Chapter 21</a>, <a href="#">Chapter 23</a> and <a href="#">Chapter 28</a>.</p> <p>A detailed list of adverse reactions is available in the vaccine's SPC, which is available from the <a href="#">electronic Medicines Compendium website</a>.</p>
<b>Reporting procedure of adverse reactions</b>	<p>Healthcare professionals and individuals/carers should report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the <a href="#">Yellow Card reporting scheme</a> or search for MHRA Yellow Card in the Google Play or Apple App Store and send a copy of the Yellow card to the Director of Public Health</p> <p>Any adverse reaction to a vaccine should also be documented in the individual's record and the individual's GP should be informed.</p> <p><b>INFORM GIBRALTAR DIRECTOR OF PUBLIC HEALTH IMMEDIATELY IF SEVERE ADVERSE REACTION IS SUSPECTED.</b></p>
<b>Written information to be given to patient or carer</b>	<p>Offer marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine.</p> <p>Immunisation promotional material may be provided as appropriate:</p> <ul style="list-style-type: none"> <li>• <a href="#">Immunisations at 1 year of age</a></li> <li>• <a href="#">Pre-school immunisations: guide to vaccinations (2 to 5 years)</a></li> </ul> <p>Available from: <a href="http://www.gov.uk/government/collections/immunisation">http://www.gov.uk/government/collections/immunisation</a></p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

<b>Patient advice / follow up treatment</b>	<p>Inform the individual/parent/carer of possible side effects and their management.</p> <p>Advise about likely timing of any fever and management of a fever.</p> <p>Advise where relevant that pregnancy should be avoided for 1 month post vaccination.</p> <p>The individual/parent/carer should be advised to seek medical advice in the event of an adverse reaction.</p> <p>When administration is postponed advise the individual/parent/carer when to return for vaccination.</p>
<b>Special considerations / additional information</b>	<p>Ensure there is immediate access to adrenaline (epinephrine) 1 in 1000 injection and access to a telephone at the time of vaccination.</p> <p>Recent data suggest that anaphylactic reactions to MMR vaccine are not associated with hypersensitivity to egg antigens. All children with egg allergy should receive the MMR vaccination as a routine procedure in primary care. MMRVaxPRO® (Sanofi Pasteur MSD) contains porcine gelatine. Priorix® (GSK) does NOT contain porcine gelatine and can be offered as an alternative to MMRVaxPRO®. Health professionals should be aware to order Priorix® when running clinics for relevant communities (see <a href="#">Vaccines and porcine gelatine</a> leaflet).</p> <p>MMR vaccine is recommended when protection against measles, mumps and/or rubella is required. MMR vaccine can be given irrespective of a history of measles, mumps or rubella infection or vaccination. There are no ill effects from vaccinating those who are already immune. If there is doubt about an individual's MMR immune status, MMR vaccine should still be given.</p> <p>Children with chronic conditions such as cystic fibrosis, congenital heart or kidney disease, failure to thrive or Down's syndrome are at particular risk from measles infection and should be immunised with MMR vaccine. MMR vaccine can be provided to children and adults of any age over 6 months using this PGD. If a dose of MMR is given before the first birthday, either because of travel to an endemic country, or because of a local outbreak, then this dose should be ignored, and two further doses given at the recommended times. Maternal antibodies may reduce the response to the first dose of vaccination up to the age of 18 months. To provide additional protection to those who fail to respond to the first dose, therefore, the second dose should not routinely be given below 18 months of age. The decision on when to vaccinate adults needs to take into consideration the past vaccination history, the likelihood of an individual remaining susceptible and the future risk of exposure and disease see the 'Green Book' <a href="#">Chapter 21</a>, <a href="#">Chapter 23</a> and <a href="#">Chapter 28</a>.</p> <p>Entry into college, university or other higher education institutions, prison or military service provides an opportunity to check an individual's</p>

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

	<p>immunisation history. Those who have not received two doses of MMR should be offered appropriate MMR immunisation.</p> <p>Pre-conceptual care, antenatal and post-natal checks provide an opportunity to assess MMR status. Individuals who have not received two doses of MMR at an appropriate interval should be offered pre- or post-natal MMR immunisation. Pregnancy should be avoided for at least 1 month following vaccination.</p> <p>Children and adults coming from abroad may not have been immunised against measles, mumps and rubella. Unless there is a reliable history of appropriate immunisation, individuals should be assumed to be unimmunised.</p> <p><b>Post Exposure</b></p> <p>Antibody responses to the rubella and mumps components of MMR vaccine do not develop soon enough to provide effective prophylaxis after exposure to these infections. However, as vaccine-induced measles antibody develops more rapidly than that following natural infection, MMR vaccine should be used to protect susceptible contacts from suspected measles. To be effective against this exposure, vaccine must be administered very promptly, ideally within three days.</p> <p>Even where it is too late to provide effective post-exposure prophylaxis with MMR, the vaccine can provide protection against future exposure to all three infections. Therefore, contact with suspected measles, mumps or rubella provides a good opportunity to offer MMR vaccine to previously unvaccinated individuals.</p> <p>If the individual is already incubating measles, mumps or rubella, MMR vaccination will not exacerbate the symptoms. In these circumstances, individuals should be advised that a measles, mumps or rubella-like illness occurring shortly after vaccination is likely to be due to natural infection. Immunoglobulin may be indicated for contacts of measles who are infants, immunosuppressed or pregnant.</p> <p>Provision of immunoglobulin is not covered by this PGD.</p>
--	---

<b>Records</b>	<p>Record:</p> <ul style="list-style-type: none"> <li>• that valid informed consent was given</li> <li>• name of individual, address, date of birth and GP with whom the individual is registered</li> <li>• name of immuniser</li> <li>• name and brand of vaccine</li> <li>• date of administration</li> <li>• dose, form and route of administration of vaccine</li> <li>• quantity administered</li> <li>• batch number and expiry date</li> <li>• anatomical site of vaccination</li> <li>• advice given, including advice given if excluded or declines immunisation</li> <li>• details of any adverse drug reactions and actions taken</li> <li>• supplied via PGD</li> </ul>
----------------	--

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

<p><b>Records</b> (Continued)</p>	<p>Records should be signed and dated (or a password controlled immuniser's record on e-records).</p> <p>All records should be clear, legible and contemporaneous.</p> <p>This information should be recorded in the individual's GP record. Where vaccine is administered outside the GP setting appropriate health records should be kept and the individual's GP informed.</p> <p>The local Child Health Information Systems team (Child Health Records Department) must be notified using the appropriate documentation/pathway as required by any local or contractual arrangement.</p> <p>A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with GHA policy.</p>
---------------------------------------	--

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

## 4. Key references

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027



<p><b>Key references</b></p>	<p><b>MMR vaccine</b></p> <ul style="list-style-type: none"> <li>• Immunisation Against Infectious Disease: The Green Book <a href="#">Chapter 21</a>, updated 31 December 2019; <a href="#">Chapter 23</a> and <a href="#">Chapter 28</a>, last updated 4 April 2013; <a href="#">Chapter 6</a> updated 26 October 2017; and <a href="#">Chapter 11</a> updated 17 March 2022</li> <li>• Summary of Product Characteristic for Priorix®, GlaxoSmithKline. 30 April 2022. <a href="http://www.medicines.org.uk/emc/medicine/2054">www.medicines.org.uk/emc/medicine/2054</a></li> <li>• Summary of Product Characteristic for MMRVAXPRO®, MSD Ltd. 15 July 2022. <a href="http://www.medicines.org.uk/emc/medicine/20968">www.medicines.org.uk/emc/medicine/20968</a></li> <li>• MSD Medical Information, Personal communication (via email), 13 December 2023</li> <li>• UKHSA National measles guidelines. Last updated 27 October 2023 <a href="https://www.gov.uk/government/publications/national-measlesguidelines">https://www.gov.uk/government/publications/national-measlesguidelines</a></li> <li>• Vaccination of individuals with uncertain or incomplete immunisation status, UKHSA. Updated 6 September 2023 <a href="http://www.gov.uk/government/publications/vaccination-of-individuals-withuncertain-or-incomplete-immunisation-status">www.gov.uk/government/publications/vaccination-of-individuals-withuncertain-or-incomplete-immunisation-status</a></li> <li>• The National Society for Phenylketonuria (NSPKU) Medical Advisory Panel: Vaccines and PKU, issued 31 January 2023 <a href="https://nspku.org/download/vaccines-and-pku/">https://nspku.org/download/vaccines-and-pku/</a></li> </ul> <p><b>General</b></p> <ul style="list-style-type: none"> <li>• NHSE Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Updated 7 March 2023 <a href="http://www.england.nhs.uk/publication/management-and-disposal-ofhealthcare-waste-htm-07-01/">www.england.nhs.uk/publication/management-and-disposal-ofhealthcare-waste-htm-07-01/</a></li> <li>• National Minimum Standards and Core Curriculum for Immunisation Training. Published February 2018 <a href="http://www.gov.uk/government/publications/national-minimum-standards-andcore-curriculum-for-immunisation-training-for-registered-healthcarepractitioners">www.gov.uk/government/publications/national-minimum-standards-andcore-curriculum-for-immunisation-training-for-registered-healthcarepractitioners</a></li> <li>• NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Last updated March 2017 <a href="http://www.nice.org.uk/guidance/mpg2">www.nice.org.uk/guidance/mpg2</a></li> <li>• NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. Updated March 2017 <a href="http://www.nice.org.uk/guidance/mpg2/resources">www.nice.org.uk/guidance/mpg2/resources</a></li> <li>• UKHSA Immunisation Collection <a href="http://www.gov.uk/government/collections/immunisation">www.gov.uk/government/collections/immunisation</a></li> </ul>
------------------------------	--

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

## Key References

(continued)

- Vaccine Incident Guidance. Last updated July 2022  
[www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors](https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors)

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

--	--

## 5. Practitioner authorisation sheet

**Measles, mumps and rubella vaccine (live):**

**Priorix®, powder and solvent for solution for injection in a pre-filled syringe**

**MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe**

**DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027**

Before signing this PGD, check that the document has had the necessary authorisations in section two. Without these, this PGD is not lawfully valid.

Practitioner

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of the <b>GHA</b> for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Measles, mumps and rubella vaccine (live):

Priorix®, powder and solvent for solution for injection in a pre-filled syringe

MMRVaxPRO®, powder and solvent for suspension for injection in a pre-filled syringe

Authors: Dr. Helen Carter DPH and Ian Bramble EN

DATE OF ISSUE 11<sup>th</sup> April 2025 DATE OF EXPIRY: 11<sup>th</sup> April 2027

--	--	--	--

Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.